ETFs Are Net Sellers of ResMed (RMD) on Oct. 16
ETFs, led by FTCS, sold $198.0 million of ResMed (RMD) shares on Oct. 16, ending a four-day buying streak. FTCS exited its position entirely, while IHI and FTGS reduced holdings. RMD, a medical device company, reported $5.65B revenue (up 10.8% YoY) and a market cap of $33.7B. Its P/E is 22.98, P/B 5.25, and P/S 6.19.
How this was made
The 30-second read
Why it matters
ETF outflows of this magnitude can trigger short‑term price declines, especially when the stock lacks other positive catalysts.
Market read
ETF-driven sell‑off creates immediate downside risk for RMD; traders may consider short positions or watch for rebound.
What to watch
Potential upcoming earnings or product announcements could offset the short‑term ETF pressure.
Background
The article details ETF activity on Oct 16, highlighting FTCS as the largest seller of ResMed shares.
Ticker impact
FTCS ETF sold $180.9 million of ResMed (RMD) on Oct 16, creating net selling pressure.
downward pressure as the market prices in the ETF sell‑off
The $180.9 M outflow represents a significant share reduction and is the primary catalyst for near‑term price movement.
Market effects
Healthcare device sector may see modest sell pressure as a large cap peer faces ETF outflows.
U.S. market participants may adjust exposure to medical‑device stocks.
Limited; impact confined to ResMed and its immediate peers.
Counterpoint
If the sell‑off is temporary, the dip could present a buying opportunity for long‑term investors.
Key entities
- companyResMed Inc.
Medical‑device maker focused on sleep‑apnea and respiratory solutions.
- ETFFTCS
ETF that reduced its ResMed holding by $180.9 M, effectively zeroing its position.
